Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OKYO PharmaFRA:OK10 24 EV-to-EBITDA is -7.37 as of Aug. 31, 2026. GuruFocus rates FRA:OK10 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 401 Biotechnology companies, OKYO Pharma ranks worse than 249376.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OKYO Pharma's enterprise value is €53.76 Mil.
OKYO Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-7.29 Mil. Therefore, OKYO Pharma's EV-to-EBITDA for today is -7.37.
The historical rank and industry rank for OKYO Pharma's EV-to-EBITDA or its related term are showing as below:
FRA:OK10'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.63 Med: 0 Max: 0
Current: -9.63
FRA:OK10's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 14.15
vs FRA:OK10: -9.63
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
OKYO Pharma's PE Ratio (TTM) for today is calculated as:
OKYO Pharma's share price for today is €1.36.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OKYO Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.207.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for OKYO Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OK10 vs ACET, ACRV, GOSS: EV-to-EBITDA Comparison
For the Biotechnology subindustry, OKYO Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OKYO Pharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OKYO Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where OKYO Pharma's EV-to-EBITDA falls into.
OKYO Pharma's current Enterprise Value is €53.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OKYO Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-7.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OKYO Pharma (FRA:OK10) has a EV-to-EBITDA of -7.37 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OKYO Pharma. According to the industry distribution chart, OKYO Pharma ranks #999999 out of 401 companies in the Biotechnology industry.
Is OKYO Pharma's EV-to-EBITDA too high?
OKYO Pharma's current EV-to-EBITDA is -7.37. Based on the distribution chart, OKYO Pharma ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OKYO Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's EV-to-EBITDA compare to ACET and ACRV?
According to the Biotechnology industry distribution chart, OKYO Pharma ranks #999999 out of 401 companies for EV-to-EBITDA. This places OKYO Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 14.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.15, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OKYO Pharma. For the Biotechnology industry, the median EV-to-EBITDA is 14.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OKYO Pharma's current EV-to-EBITDA is -7.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (FRA:OK10) has a current EV-to-EBITDA of -7.37. The current EV-to-EBITDA is -7.37. OKYO Pharma's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For OKYO Pharma (FRA:OK10), the current EV-to-EBITDA is -7.37 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
24GF Score
Get the complete analysis for FRA:OK10
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OK10 has been successfully added to your 
